RxDoctor Payments Data

Sumera Pervaiz

Family Medicine · Augusta, GANPI 1619382009

Payments from drug & device makers

$2,200in general payments, 2019–2025

Across 112 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$483
  • Astellas Pharma US Inc$192
  • AstraZeneca$177
  • Pfizer$174
  • Lilly USA, LLC$171
  • AbbVie$141
  • plus $863 from 22 others

What the payments were for

  • Food & beverage$2,11096%
  • Education$904%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,200 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$76,220
Medicare patients
191
Services billed
1,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide71$96,735
OzempicSemaglutide49$70,670
SynthroidLevothyroxine Sodium13$1,669
Rosuvastatin Calcium93$1,154
Albuterol Sulfate HfaAlbuterol Sulfate46$1,045
Boostrix TdapDiphth,pertuss(Acell),tet Vac14$976
Valsartan13$754
Atorvastatin Calcium102$706
Candesartan Cilexetil12$603
Gabapentin24$492
Metformin Hcl ErMetformin Hcl38$491
Losartan Potassium55$457
Escitalopram Oxalate50$444
Duloxetine Hcl15$407
Levothyroxine Sodium77$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$171$96,73571 claims
Novo NordiskOzempic$483$70,67049 claims
AbbVieSynthroid$141$1,66913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →